Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Pharmaron Receives $186 Million Grant to Expand UK Cell/Gene Therapy Manufacturing

publication date: Mar 29, 2023

Pharmaron Beijing received a $186 million grant from the UK to expand its Liverpool viral vector and DNA manufacturing facilities, adding more than 8,000 square meters. Pharmaron, a CDMO with operations in China, the US and UK, acquired the cell and gene facility in 2021 from AbbVie, which was divesting the Allergan-built facility after it acquired the company. Pharmaron said the expansion will provide a four-fold increase in gene therapy process development and analytical capacity for viral vector, DNA and RNA drug development, plus drug product formulation and commercial scale GMP capacity in the future. More details...

Stock Symbols: (SHZ: 300759l HK: 3759)

Share this with colleagues: